Jupiter Life Line Hospitals Limited JLHL NSEPHARMA

Healthcare · Medical Care Facilities · India

https://www.jupiterhospital.com

Jupiter Life Line Hospitals Limited, a multi-specialty hospital, provides health care services under the Jupiter brand in India. The company offers treatments in the areas of bariatric surgery, breast care center, cardiac surgery, cardiology, chest medicine, dental care, dermatology, endocrinology and diabetes, ENT, gastroenterology, general surgery and minimal access surgery, hematology and BMT, HPB and surgical gastroenterology, infectious diseases, internal medicine, interventional radiology, mental health, nephrology, neurology, neurosurgery, nutrition and dietetics, Obs and gynecology, oncology, ophthalmology, organ transplant, orthopedics, pediatrics, pain clinic, plastic and cosmetic surgery, rehabilitation, rheumatology, robotic knee replacement, robotic surgery, TAVI/TAVR, and urology. It also operates hotel under the Fortune Park Lake City Hotel name in Thane. The company was incorporated in 2002 and is based in Mumbai, India.

Market & Price

Market Cap

₹8,701.27 Cr

Current Price

₹1,327.10

High / Low (52W)

₹1,593.98 / ₹1,198.99

Beta

0.16

Valuation

Stock P/E

44.85

Industry PE

37.60

Forward P/E

30.71

PEG Ratio

Book Value

₹235.30

Price to Book

5.64

P/S

5.80

EV/EBITDA

25.49

Dividend Yield

0.08%

Profitability & Returns

ROCE

13.59%

ROE

13.39%

ROA

7.45%

Profit Margin

12.94%

Op Margin

16.99%

EPS (Latest Qtr)

₹7.66

EPS (TTM)

₹29.59

Balance Sheet & Liquidity

Debt/Equity

0.38

Quick Ratio

2.76

Current Ratio

3.02

Debt

₹584.24 Cr

Total Assets

₹2,383.13 Cr

Current Assets

₹684.90 Cr

Working Capital

₹458.32 Cr

Ownership

Promoter Holding

67.00%

Chg in Prom Hold

FII / Inst Holding

20.76%

Chg in FII Hold

Financial Snapshot

Enterprise Value

₹8,749.17 Cr

Total Revenue (TTM)

₹1,499.79 Cr

EBITDA

₹343.26 Cr

Free Cash Flow

₹-266.38 Cr

Operating Cash Flow

₹267.71 Cr

Shares Outstanding

₹6.56 Cr

Gross Margin

63.75%

Payout Ratio

3.39%

Growth (CAGR)

Revenue 5Y

18.89%

Profit 5Y

38.67%

Revenue (YoY)

17.10%

Earnings (YoY)

12.00%

PROS

Compounding revenue at 18.9% over 5 years.
Profit CAGR of 38.7% over 5 years.

CONS

In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP ₹	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	JLHL Jupiter Life Line Hospitals Limited NSEPHARMA	1,327.10	44.85	₹8,701.27 Cr	0.08%	13.59%	13.39%	18.89%	38.67%
2	SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA	1,799.20	37.59	₹4.32 L Cr	0.92%	17.94%	14.72%	10.39%	10.65%
3	DIVISLAB Divi's Laboratories Limited NSEPHARMA	6,667.00	68.97	₹1.77 L Cr	0.45%	18.96%	16.19%	11.27%	12.08%
4	TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA	4,410.80	68.96	₹1.49 L Cr	0.86%	9.06%	16.98%	13.27%	20.21%
5	CIPLA Cipla Limited NIFTY50NSEAIPHARMA	1,401.00	29.16	₹1.13 L Cr	0.93%	14.88%	11.74%	7.23%	11.45%
6	DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA	1,303.50	25.90	₹1.09 L Cr	0.61%	14.00%	11.83%	10.96%	-2.35%
7	ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA	1,077.70	21.51	₹1.08 L Cr	0.09%	19.24%	18.32%	16.55%	36.99%
8	LUPIN Lupin Limited NIFTY_MIDNSEPHARMA	2,267.70	19.49	₹1.04 L Cr	0.53%	28.42%	26.91%	19.10%	131.46%
9	MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA	2,375.60	51.29	₹98,090.71 Cr	0.08%	13.78%	12.45%	17.73%	14.28%

Quarterly Results

Figures in INR.

Metric	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	336.66 Cr	347.62 Cr	393.63 Cr	365.37 Cr	387.84 Cr
Cost of Revenue	67.41 Cr	68.36 Cr	73.76 Cr	69.04 Cr	73.74 Cr
Gross Profit	269.26 Cr	279.26 Cr	319.87 Cr	296.32 Cr	314.10 Cr
Operating Expenses	207.21 Cr	222.34 Cr	249.09 Cr	234.60 Cr	248.19 Cr
Operating Income	62.05 Cr	56.92 Cr	70.79 Cr	61.73 Cr	65.91 Cr
EBITDA	86.58 Cr	90.99 Cr	103.52 Cr	86.16 Cr	99.82 Cr
Interest Expense	5.61 Cr	8.26 Cr	7.84 Cr	7.55 Cr	9.01 Cr
Pretax Income	63.32 Cr	61.53 Cr	74.22 Cr	56.91 Cr	67.56 Cr
Tax Provision	18.04 Cr	17.66 Cr	16.75 Cr	14.41 Cr	17.29 Cr
Net Income	44.00 Cr	43.84 Cr	57.48 Cr	42.55 Cr	50.62 Cr
Diluted EPS	6.89	6.69	8.75	5.49	7.66

Profit & Loss (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Revenue	-	892.54 Cr	1,069.50 Cr	1,302.40 Cr	1,499.79 Cr
Cost of Revenue	-	181.15 Cr	214.01 Cr	255.48 Cr	287.27 Cr
Gross Profit	-	711.39 Cr	855.49 Cr	1,046.92 Cr	1,212.52 Cr
Operating Expenses	-	547.58 Cr	654.11 Cr	803.88 Cr	956.90 Cr
Operating Income	-	163.81 Cr	201.38 Cr	243.03 Cr	255.62 Cr
EBITDA	-	206.01 Cr	260.46 Cr	328.46 Cr	380.74 Cr
Interest Expense	-	38.74 Cr	22.66 Cr	10.71 Cr	32.66 Cr
Pretax Income	-	128.71 Cr	195.41 Cr	260.68 Cr	260.44 Cr
Tax Provision	-	55.80 Cr	18.80 Cr	66.92 Cr	66.25 Cr
Net Income	-	72.91 Cr	176.61 Cr	192.03 Cr	194.41 Cr
Diluted EPS	-	11.12	28.44	29.47	29.53

Compounded Sales Growth

5 Years:	18.89%
1 Year:	17.10%

Compounded Profit Growth

5 Years:	38.67%
1 Year:	12.00%

Stock Price Performance

1 Year:	-7.95%
6 Months:	-9.71%
3 Months:	+9.61%
1 Month:	+6.12%

Balance Sheet (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Total Assets	-	985.53 Cr	1,281.33 Cr	1,904.89 Cr	2,383.13 Cr
Current Assets	-	209.26 Cr	409.76 Cr	687.05 Cr	684.90 Cr
Cash & Equivalents	-	134.46 Cr	23.01 Cr	368.32 Cr	54.76 Cr
Inventory	-	19.00 Cr	21.34 Cr	24.10 Cr	38.34 Cr
Receivables	-	45.69 Cr	57.21 Cr	41.89 Cr	75.54 Cr
Total Liabilities	-	621.62 Cr	112.59 Cr	548.64 Cr	839.04 Cr
Current Liabilities	-	132.14 Cr	105.75 Cr	152.43 Cr	226.57 Cr
Long Term Debt	-	452.51 Cr	0	321.75 Cr	500.90 Cr
Total Debt	-	468.63 Cr	0	393.14 Cr	584.24 Cr
Total Equity	-	365.69 Cr	1,169.04 Cr	1,356.24 Cr	1,544.08 Cr
Shares Outstanding	-	6.56 Cr	6.56 Cr	6.56 Cr	6.56 Cr

Cash Flows (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow	-	117.17 Cr	114.52 Cr	266.74 Cr	267.71 Cr
Investing Cash Flow	-	-103.57 Cr	-246.14 Cr	-497.33 Cr	-441.93 Cr
Financing Cash Flow	-	17.50 Cr	128.16 Cr	296.70 Cr	136.47 Cr
Capital Expenditure	-	-77.24 Cr	-85.30 Cr	-327.59 Cr	-501.85 Cr
Free Cash Flow	-	39.92 Cr	29.23 Cr	-60.85 Cr	-234.14 Cr
Net Change in Cash	-	31.10 Cr	-3.47 Cr	66.11 Cr	-37.76 Cr

Ratios (Annual)

Figures in %.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Gross Margin %	-	79.7%	80.0%	80.4%	80.8%
Operating Margin %	-	18.4%	18.8%	18.7%	17.0%
Net Margin %	-	8.2%	16.5%	14.7%	13.0%
ROE %	-	19.9%	15.1%	14.2%	12.6%
ROCE %	-	19.2%	17.1%	13.9%	11.9%

Shareholding Pattern

Insiders

67.00%

Institutions

20.76%

Public Float

62.91%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for JLHL

No recent headlines available.

JLHL · Healthcare